Novogenia AG Joins 10XREVIV Initiative with DNA Analysis and Supplements

Novogenia AG, a company specializing in genetic insights and personalized health products, announced its participation in a clinical study under the 10XREVIV initiative in Abu Dhabi. This study focuses on combining DNA analytics with personalized dietary supplements alongside GLP-1 therapies. The initiative aligns with Novogenia’s strategy for international growth.

Novogenia will analyze DNA, evaluate results, and develop personalized supplements for study participants. The study aims to explore the additional benefits these tailored supports can provide to those undergoing GLP-1 therapy, particularly in weight management and adherence to treatment.

The study, in collaboration with healthcare partners such as M42 and 10X Health, seeks to include 500 participants. It will assess the nutritional impact, muscle and fat percentages, and overall well-being of participants. The initiative aligns with the global growth of GLP-1 therapies, projected to increase significantly in market size by 2033.